Last reviewed · How we verify
Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Chronic- PF-06480605 150 mg SC Q4W | chronic-pf-06480605-150-mg-sc-q4w | Pfizer | Janus kinase inhibitor | JAK1 and JAK2 enzymes |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis:
- Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis treatment updates — RSS
- Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis treatment updates — Atom
- Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-ankylosing-spondylitis-and-crohn-s-disease-and-ulcerative-colitis. Accessed 2026-06-10.
Related
- Moderate to severe ankylosing spondylitis and Crohn's disease and ulcerative colitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing